Tagged Articles

Januvia 202 articles

Type 2 diabetes drugs linked to inflammatory bowel disease

A class of type 2 diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors may increase the risk of inflammatory bowel disease, according to a new study published in the peer-reviewed medical journal, The BMJ. DPP-4 inhibitors include the brand name type 2 diabetes medications Januvia, Onglyza and Tradjenta. DPP4 inhibitors work to reduce blood sugar levels by blocking the action of DPP-4, an enzyme that destroys the hormone incretin. Incretins help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. The population-based cohort ... Read More

Class of diabetes drugs may cause painful blistering skin condition

A class of type 2 diabetes treatments may cause users to develop large fluid-filled blisters called bullous pemphigoid. The Food and Drug Adminsitration (FDA) received enough reports of pemphigoid in patients who were treated with diabetes treatments known as DPP-4 inhibitors that it was listed in the agency’s latest quarterly Potential Signals of Serious Risks/New Safety Information for April to June 2016. DPP-4 (dipeptidyl peptidase 4) inhibitor medications include the brand names Glyxambi, Kazano, Janumet, Janumet XR, Januvia, Jentadueto XR, Jentadueto, Kombiglyze XR, Nesina, Onglyza, Oseni, and Tradjenta. The first DPP-4 inhibitor hit the market in 2006. According to the ... Read More

SGLT2 inhibitors linked to acute pancreatitis

A painful inflammation of the pancreas called acute pancreatitis is a potential new safety issue identified with the new class of type 2 diabetes treatments known as SGLT2 inhibitors. The side effect was identified through the Food and Drug Administration (FDA) adverse event tracking database, which identifies potential hazards with drugs each quarter. The FDA identifies potentially harmful side effects with medications to determine if further action – such as additional or strengthened warnings – are required. The agency said it is currently evaluating the need for regulatory action regarding the link between SGLT2 inhibitors and acute pancreatitis. SGLT2 inhibitors ... Read More

Large analysis of three clinical trials links diabetes drugs gliptins to acute pancreatitis

An analysis of three large clinical trials looking at the cardiovascular safety of three type 2 diabetes drugs known as gliptins has found that the medications significantly increase the risk of acute pancreatitis. The study, conducted by Ivan Tkac, M.D., Ph.D., from Pasteur University Hospital in Kosice, Slovakia, and Itamar Raz, M.D., from Hadassah Hebrew University Hospital in Jerusalem, combined incidence of acute pancreatitis from randomized controlled trials. The trials included SAVOR-TIMI 53, involving the medication Onglyza (saxagliptin); EXAMINE, involving the drug Nesina (alogliptin); and TECOS, involving the drug Januvia (sitagliptin). Combined, the studies involved 18,238 gliptin-treated patients and 18,157 ... Read More

Type 2 diabetes drugs linked to cancer spread

Two widely used type 2 diabetes drugs, which are also antioxidants, appear to stimulate cancer metastasis in laboratory mice, a new study has found. The research narrowed in on antioxidants and the popular notion that adding them to the diet can prevent cancer, slow aging as well as a slew of other health benefits. Granted, antioxidants found in foods like fruits and vegetables have been found to neutralize free radicals that can damage DNA, which can lead to cancer. This idea has fostered the belief that antioxidants can also prevent cancer. But, studies on antioxidant pills sold as dietary supplements ... Read More

Type 2 diabetes drug Januvia increases risk of acute pancreatitis

People who take type 2 diabetes medications such as Januvia have a small but statistically significant increased risk of developing a painful inflammation of the pancreas known as acute pancreatitis, according to a new meta-analysis from three major clinical trials. Januvia, know chemically as sitagliptin, was approved by the Food and Drug Administration in 2006, becoming the first in a new class of type 2 diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Since then, several other DPP-4 inhibitors have hit the market including Janumet, Onglyza, Tradjenta and Nesnia. DPP-4 inhibitors are a subclass of diabetes drugs called incretin mimetics. ... Read More

Type 2 diabetics at greater risk of developing pancreatic, liver cancers

People with type 2 diabetes who were hospitalized at some point to treat their disease are at an increased risk of developing certain types of cancer, a new study has found. Researchers at Lund University in Sweden; Germany Cancer Research Center in Heidelberg, Germany; and Stanford University in California analyzed data from a national Swedish database and found type 2 diabetics were more likely to have cancer. The most common cancers among these patients affected the colon, liver, pancreas, endometrium, and kidney. The risk for pancreatic cancer and liver cancer in these patients was particularly high, the researchers noted. Pancreatic ... Read More

Victoza claims better efficacy than Invokana

Novo Nordisk is taking great efforts to stretch the profit-earning potential of its blockbuster type 2 diabetes drug Victoza. The company won approval to market the drug as an obesity treatment under the brand name Saxenda, and has launched clinical trials to test the drug as a treatment for nonalcoholic fatty liver disease, one of the most common causes of chronic liver disease. Now the company is taking aim at its competitors in the lucrative diabetes market, rolling out a new meta-analysis showing that Victoza was superior at reducing blood sugar metric HbA1c (a more accurate test for diabetes control) ... Read More

Pancreatitis rate dramatically increasing in recent years

Pancreatitis, a painful inflammation of the pancreas, is the most common cause of hospitalization for patients with a gastrointestinal disorder. The number of those afflicted with the condition has nearly doubled in the past two decades, with more than 40-60 new cases per 100,000 diagnosed each year. Researchers say the cause for the increase in pancreatitis is likely linked to the growing problem of obesity, which is strongly related to gallstones, as well as increasing amounts of alcohol consumption. Pancreatitis can be acute, meaning it occurs suddenly and usually resolves within days if treated in a timely manner, or chronic, ... Read More

Patients with Type 2 diabetes sought for clinical trial comparing medications

More than 50 medical centers associated with universities across the country are recruiting patients with type 2 diabetes to participate in a five-year study to determine the best prescription drug to treat high blood sugar. The study is being conducted by National Institute of Diabetes and Digestive and Kidney Diseases. A total of 5,000 participants is being sought. Those who wish to join the clinical trial should have been diagnosed with type 2 diabetes within the past 10 years and currently be taking the widely used anti-diabetes drug Metformin. Those who are accepted into the program will receive compensation for their ... Read More